Vetoquinol SA: directors' dealings · France · AMF

About Vetoquinol SA

Vetoquinol SA is an independent veterinary pharmaceutical company focused on animal health. Listed on Euronext Paris since 2006 under the ticker VETO, the group serves two main end markets: companion animals, especially dogs and cats, and farm animals, notably cattle and pigs. Its business model covers the research, development, manufacturing and marketing of veterinary medicines as well as non-medicated products used to prevent, treat or support animal health conditions. In 2025, the company generated annual sales of €525.7 million, with a significant contribution from its Essentials portfolio, which has become a strategic engine for growth and profitability. Vetoquinol is therefore one of the leading international players in animal health, with operations across Europe, the Americas and Asia-Pacific. The company’s history dates back to 1933, when Joseph Frechin founded Vetoquinol in Lure, in eastern France. Since its origins, the group has followed a specialization strategy built around independence, scientific expertise and a strong veterinary focus. This family-rooted entrepreneurial background remains a core differentiator compared with many peers that are part of larger diversified pharmaceutical groups. Over time, Vetoquinol has expanded through a combination of targeted acquisitions, product innovation and international development, building a portfolio that is well established among veterinarians and animal owners. Vetoquinol markets solutions across several key therapeutic areas, including anti-infectives, anti-inflammatories, dermatology, pain management, locomotion, parasitology, reproduction and supportive care. The company addresses the everyday needs of veterinarians while also serving breeders and pet owners. A central pillar of the strategy is the “Essentials” category, made up of core products with strong recurring demand and potential to become market leaders. This segment supports revenue visibility and reflects the group’s emphasis on products with durable demand and broad clinical relevance. Vetoquinol also stands out for its commitment to innovation, customer proximity and local adaptation through a network of subsidiaries and distributors. Geographically, the group benefits from a diversified footprint that reduces exposure to any single market and helps balance business cycles across regions. This international presence supports resilience and provides access to markets with varying growth dynamics. Notable facts about Vetoquinol include its long operating history of more than 90 years, its status as a pure-play animal health specialist, and its position among the top global players in its industry. The company’s profile is also underpinned by favorable structural trends, such as rising veterinary care spending, increased pet ownership and the ongoing professionalization of livestock health management.